Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: A randomized controlled trial

JAMA

Volumn 302, Issue 2, 2009, Pages 159-167

  Van Gils, Elske J M ^a,c   Veenhoven, Reinier H ^c   Hak, Eelko ^a,b,d   Rodenburg, Gerwin D ^a,c   Bogaert, Debby ^a   IJzerman, Ed P F ^e   Bruin, Jacob P ^e   Van Alphen, Loek ^f   Sanders, Elisabeth A M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Infection and Immunology   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Laboratory of Public Health Haarlem   (Netherlands)

^f NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CRM 197 PCV 7; DIPHTHERIA TOXOID CRM197; DIPHTHERIA TOXOID CRM197 HEPTAVALENT PNEUMOCOCCUS CONJUGATE VACCINE; HEPTAVALENT PNEUMOCOCCUS CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; VACCINE;

ADULT; ARTICLE; BACTERIUM CARRIER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; INFANT; MALE; MICROBIOLOGICAL EXAMINATION; NASOPHARYNX; NASOPHARYNX SWAB; NETHERLANDS; NORMAL HUMAN; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; CLASSIFICATION; HETEROZYGOTE; IMMUNIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; NEWBORN; SEROTYPING;

CARRIER STATE; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 67650169801     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.975     Document Type: Article

References (42)

1. Black S, Shinefield H, Fireman B, et al; Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19(3):187-195.
2. Eskola J, Kilpi T, Palmu A, et al; Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl JMed. 2001;344(6):403-409.
3. Lexau CA, Lynfield R, Danila R, et al; Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043-2051.
4. Whitney CG, Farley MM, Hadler J, et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18): 1737-1746.
5. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369(9568):1179-1186.
6. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.JAMA. 2006;295(14):1668-1674.
7. Whitney CG. Impact of conjugate pneumococcal vaccines. Pediatr Infect Dis J. 2005;24(8):729-730.
8. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25(6):494-501.
9. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: amatched case-control study. Lancet. 2006;368(9546):1495-1502.
10. Goldblatt D, Southern J, Ashton L, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 2006;25 (4):312-319.
11. Vestrheim DF, Lovoll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008;26(26):3277-3281.
12. Centers for Disease Control and Prevention (CDC). Progress in introduction of pneumococcal conjugate vaccine - worldwide, 2000-2008. MMWRMorb Mortal Wkly Rep. 2008;57(42):1148-1151.
13. Jones VF, Harrison C, Stout GG, Hopkins J. Nasopharyngeal colonization with heptavalent pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae with prolonged vaccine dosing intervals. Pediatr Infect Dis J. 2005;24(11):969-973.
14. Trotter CL,McVernon J, Ramsay ME, et al; SAGE subgroup. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine. 2008;26(35):4434-4445.
15. Käyhty H, Auranen K, Nohynek H, Dagan R, Mäkelä H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines. 2006; 5(5):651-667.
16. Watt JP, O'Brien KL, Katz S, et al. Nasopharyngeal versus oropharyngeal sampling for detection of pneumococcal carriage in adults. J Clin Microbiol. 2004;42(11):4974-4976.
17. O'Brien KL, Nohynek H; World Health Organization Pneumococcal Vaccine Trials Carriage Working Group. Report from aWHOWorking Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J. 2003;22(2):e1-e11.
18. Veenhoven RH, Bogaert D, Schilder AG, et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clin Infect Dis. 2004;39(7): 911-919.
19. Bogaert D, van Belkum A, SluijterM, et al. Colonisation by Streptococcus pneumoniae and Staphy-lococcus aureus in healthy children. Lancet. 2004; 363(9424):1871-1872.
20. Harrell FE Jr. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer; 2001.
21. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1):121-130.
22. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049-1060.
23. Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316(7139):1236-1238.
24. O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis. 2007;196(8):1211-1220.
25. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis. 1999;180 (4):1171-1176.
26. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet. 1996;348(9022):271-272.
27. Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on naso-pharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis. 2004; 39(7):930-938.
28. Käyhty H, Ahman H, Eriksson K, Sorberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J. 2005; 24(2):108-114.
29. Goldblatt D, Hussain M, Andrews N, et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis. 2005;192(3):387-393.
30. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007; 25(19):3816-3826.
31. Jokinen JT, Ahman H, Kilpi TM, Makela PH, Kayhty MH. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis. 2004;190 (3):545-550.
32. Obaro SK, Adegbola RA, Chang I, et al. Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr Infect Dis J. 2000;19(5):463-469.
33. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4(3): 144-154.
34. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784-1792.
35. Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med. 2006; 144(1):1-9.
36. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196 (9):1346-1354.
37. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis. 2006; 193(11):1487-1494.
38. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child. 2002;86(6):396-399.
39. Kelly DF,Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology. 2004; 113(2):163-174.
40. Centers for Disease Control and Prevention (CDC). Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae - Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep. 2007; 56(41):1077-1080.
41. Huebner RE, Dagan R, Porath N, Wasas AD, Klugman KP. Lack of utility of serotyping multiple colonies for detection of simultaneous nasopharyngeal carriage of different pneumococcal serotypes. Pediatr Infect Dis J. 2000;19(10):1017-1020.
42. Bogaert D, Engelen MN, Timmers-Reker AJ, et al. Pneumococcal carriage in children in the Netherlands: a molecular epidemiological study. J Clin Microbiol. 2001;39(9):3316-3320.